Liu et al. Respond to “Epstein-Barr Virus Screening for Nasopharyngeal Carcinoma”.

The article presents Liu Z, Ji MF, Huang QH's response to the invitory commentary on the article 'Two Epstein-Barr virus–related serologic antibody tests in nasopharyngeal carcinoma (NPC) screening: results from the initial phase of a cluster randomized controlled trial in southern China' by Dr. Hildesheim. The article also discusses risk prediction model incorporating other risk factors can be used to improve the efficiency of NPC screening in both endemic and nonendemic areas.